Pneumococcal Vaccines Clinical Trial
Official title:
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels (Low: 1.1 mcg; Mid: 2.2 mcg; or Mixed: 2.2/4.4 mcg) compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels (Low: 1.1 mcg; Mid: 2.2 mcg; or Mixed: 2.2/4.4 mcg) compared to PCV20 in adults aged 50 to 64 years of age. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01953510 -
Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam
|
Phase 2/Phase 3 | |
| Completed |
NCT05540028 -
Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
|
Phase 1 | |
| Recruiting |
NCT05298800 -
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
|
Phase 4 | |
| Active, not recruiting |
NCT06077656 -
Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
|
Phase 2 | |
| Active, not recruiting |
NCT06151288 -
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06000397 -
Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age
|
N/A | |
| Completed |
NCT00574548 -
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
|
Phase 3 | |
| Not yet recruiting |
NCT06271681 -
Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
|
Phase 4 | |
| Active, not recruiting |
NCT05844423 -
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
|
Phase 2 | |
| Completed |
NCT00824655 -
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children
|
Phase 3 | |
| Completed |
NCT01646398 -
A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older
|
Phase 3 | |
| Completed |
NCT00464945 -
Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
|
Phase 3 | |
| Completed |
NCT03893448 -
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
|
Phase 3 | |
| Completed |
NCT05297578 -
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
|
Phase 2 | |
| Completed |
NCT01964716 -
13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.
|
Phase 3 | |
| Completed |
NCT01537185 -
Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults
|
Phase 1 | |
| Recruiting |
NCT00999739 -
Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
|
Phase 3 | |
| Not yet recruiting |
NCT05721456 -
Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil.
|
Phase 3 | |
| Active, not recruiting |
NCT02012309 -
Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses
|
N/A | |
| Completed |
NCT01392378 -
Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
|
Phase 4 |